Centessa Pharmaceuticals
Centessa Pharmaceuticals is focused on developing transformative treatments for sleep-wake disorders, hemophilia B, and cancer through its innovative programs and technologies.
Centessa Pharmaceuticals Services
Centessa Pharmaceuticals focuses on discovering and developing medicines that aim to transform patient care. The company's activities span from early discovery stages to late-stage development, addressing various therapeutic areas. Their expertise includes innovative treatments for sleep-wake disorders, bleeding disorders like hemophilia B, and advanced solid tumors through their LockBody® technology platform. This broad spectrum of services emphasizes their commitment to offering advanced, effective therapeutic solutions across medical domains.
Centessa Pharmaceuticals Orexin Receptor 2 Agonist Program
Centessa Pharmaceuticals is actively developing ORX750, an investigational, orally-administered, highly potent, and selective orexin receptor 2 (OX2R) agonist. ORX750 was designed using structure-based drug design capabilities, high-resolution protein crystallography, and cryo-EM. The program notably includes a Phase 1 first-in-human clinical trial aimed at treating narcolepsy, reflecting Centessa's dedication to providing innovative treatment options for patients with sleep-wake disorders.
SerpinPC and Hemophilia B
Centessa Pharmaceuticals is advancing SerpinPC, a novel subcutaneous treatment targeting hemophilia B, with potential applications in other bleeding disorders. SerpinPC works by allowing more thrombin to be generated by inhibiting activated protein C (APC). This investigational biologic is currently being evaluated in ongoing registrational PRESent-2 and PRESent-3 studies. The company's hemophilia program underscores its commitment to addressing significant unmet needs in the treatment of rare bleeding disorders.
LockBody® Technology Platform in Immuno-Oncology
Centessa Pharmaceuticals' LockBody® technology platform aims to revolutionize immuno-oncology treatment by selectively driving potent effector function activity to the tumor microenvironment while avoiding systemic toxicity. LB101, an example of this innovative platform, is in a Phase 1/2 first-in-human trial for the treatment of advanced solid tumors. This platform seeks to address unmet needs in cancer therapy, underscoring Centessa's commitment to developing next-generation cancer treatments focused on safety and efficacy.
Centessa Pharmaceuticals Public Offering
Centessa Pharmaceuticals announced the pricing of a $100 million public offering of American Depositary Shares. This financial milestone is highlighted as part of the company's broader strategy to secure funding for the continued development and advancement of their pipeline programs. The capital raised through this public offering aims to support ongoing and future initiatives aimed at discovering and developing transformational medicines.